Welcome to our dedicated page for Contineum Therapeutics news (Ticker: CTNM), a resource for investors and traders seeking the latest updates and insights on Contineum Therapeutics stock.
Contineum Therapeutics, Inc. (CTNM) generates a steady flow of news as a clinical-stage biopharmaceutical company focused on novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications. News coverage for CTNM often centers on clinical trial milestones, topline data readouts and capital markets activity related to its lead programs PIPE-791 and PIPE-307.
Investors following CTNM news can expect updates on clinical development, including Phase 1b and Phase 2 trials in idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain and major depressive disorder. The company has reported positive topline data from a Phase 1b PET trial of PIPE-791, topline results from the PIPE-307 VISTA Phase 2 trial in relapsing-remitting multiple sclerosis, and regular progress reports on planned global Phase 2 studies in idiopathic pulmonary fibrosis.
Contineum’s news flow also includes financial results and financing transactions. The company issues quarterly financial updates and has announced both at-the-market offerings and underwritten public offerings of Class A common stock, including an upsized public offering under an effective shelf registration statement. These items provide context on how Contineum funds its research and development plans.
Additional CTNM headlines cover investor conference participation, regulatory and trial design disclosures, and collaborations such as the global license and development agreement with Janssen Pharmaceutica NV for PIPE-307. For readers tracking the CTNM stock, this news page offers a centralized view of material events, clinical data announcements and corporate developments affecting Contineum Therapeutics.
Contineum Therapeutics (NASDAQ: CTNM) has reported its Q4 2024 financial results and clinical development milestones. The company ended Q4 2024 with $204.8 million in cash and equivalents, projecting runway through 2027.
Key upcoming milestones include:
- PIPE-791 Phase 1b PET trial topline data expected in Q2 2025
- PIPE-307 Phase 2 VISTA trial data for RRMS treatment anticipated in H2 2025
- Phase 2 proof-of-concept trials for IPF and PrMS planned for H2 2025
- PIPE-791 Phase 1b chronic pain trial topline data expected in early 2026
Financial highlights show R&D expenses at $13.0 million (62% increase YoY), G&A expenses at $4.0 million, and a net loss of $14.6 million for Q4 2024.
Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in a Phase 1b trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting chronic pain treatment. The randomized, double-blind, placebo-controlled, crossover trial will evaluate the drug's safety, tolerability, and pain reduction effectiveness.
The study focuses on chronic pain associated with osteoarthritis (OA) and low back pain (LBP). The trial will enroll approximately 40 patients across five U.S. sites, with a 28-day treatment duration. Topline data is expected in early 2026.
PIPE-791 works by blocking the lysophosphatidic acid 1 receptor (LPA1R), potentially modifying maladaptive changes in the central nervous system associated with chronic pain. The drug aims to provide a non-opioid treatment alternative for patients suffering from OA and LBP.
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the 2025 Leerink Partners Global Healthcare Conference.
The company's management will deliver a presentation on Tuesday, March 11th at 3:00 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM) has completed enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis (RRMS). The trial, designed to assess safety and efficacy, will evaluate multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients.
PIPE-307, being developed under a global license agreement with Janssen Pharmaceutica NV, is positioned as a potentially first-in-class M1 receptor antagonist. The Phase 2 study is randomized, double-blind, placebo-controlled, and multi-center. The last patient is expected to complete the trial in Q3 2025, with enrollment completion achieved ahead of schedule in December 2024.
Contineum Therapeutics (NASDAQ: CTNM) has initiated patient dosing in its Phase 1b PET trial for PIPE-791, a novel brain penetrant small molecule antagonist targeting the LPA1 receptor. The open-label, single-center trial aims to evaluate receptor occupancy in the brain and lungs of multiple patient cohorts, including healthy volunteers, idiopathic pulmonary fibrosis (IPF), and progressive multiple sclerosis (PrMS) patients.
The study will measure the correlation between pharmacokinetics and receptor occupancy using PET imaging. The company expects to release topline data in the second quarter of 2025. The trial is registered under NCT06683612.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company's management will engage in a fireside chat on December 4, 2024, at 11:15 a.m. ET in Miami. The event will be accessible via audio webcast through Contineum's website's Investors section, with a replay option available.
Contineum Therapeutics (NASDAQ: CTNM) received FDA authorization for its IND application for PIPE-791, targeting chronic pain treatment. The company plans to commence a Phase 1b study in Q1 2025 for osteoarthritis and low back pain treatment. The study will be randomized, double-blind, placebo-controlled, involving approximately 40 patients across five sites with a 28-day treatment duration. Topline data is expected in early 2026. PIPE-791 is a novel brain penetrant small molecule antagonist of LPA1R, targeting neuropathic pain components. The company's cash position of $213.9 million is expected to fund operations through 2027.
Contineum Therapeutics (NASDAQ: CTNM), a clinical stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology conditions, has announced its participation in two major investor conferences in November 2024.
The company will attend the Stifel 2024 Healthcare Conference in New York on November 18, where CEO Carmine Stengone will present at 4:10 p.m. ET. Additionally, management will participate in one-on-one meetings at the Jefferies 2024 London Healthcare Conference on November 21. The Stifel presentation will be available via webcast on Contineum's website with replay access.
Contineum Therapeutics (Nasdaq: CTNM) reported its Q3 2024 financial results and recent business highlights. The company continued enrolling patients in its Phase 2 VISTA trial of PIPE-307 for RRMS, achieving two-thirds enrollment. It expects full enrollment by H1 2025. Contineum submitted a CTA to the MHRA for a Phase 1b trial of PIPE-791, targeting healthy volunteers and patients with progressive multiple sclerosis and IPF, aiming to start in December 2024. Janssen Pharmaceutica remains on track to start a Phase 2 trial of PIPE-307 in depression. The company holds $214 million in cash, expected to support operations through 2027. Q3 R&D expenses rose to $9.7 million from $6.5 million YoY, driven by increased costs for ongoing trials and toxicology studies. General and administrative expenses also increased to $3.3 million from $1.6 million YoY, mainly due to higher stock-based compensation and consulting costs.
Contineum Therapeutics (Nasdaq: CTNM), a clinical stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. The company, which focuses on developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications, will be represented by its President and CEO, Carmine Stengone.
The conferences are:
- Morgan Stanley 22nd Annual Global Healthcare Conference (September 4-6, 2024, New York) - Presentation on September 4 at 7:00 am ET
- H.C. Wainwright 26th Annual Global Investment Conference (September 9-11, 2024, New York) - Presentation on September 10 at 2:30 pm ET
Both presentations will be available via webcast on Contineum's website, with replays accessible after the events conclude.